Clinical Trial Update: The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study [NA]

View source ↗

Summary

A retrospective study evaluating the effectiveness and safety of first-line Atezolizumab plus Bevacizumab combined with HAIC in high-risk hepatocellular carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma (HCC) | NA | Status: COMPLETED